Abstract: Silicone oil-containing formulation for nasal application for use in a method for intranasal treatment of endogenous diseases of the nose and/or those due to exogenous causes, e.g. those which are caused by bacteria, fungi, viruses and/or allergens, wherein the silicone oil or the formulation is optionally enriched with oxygen, preferably in the presence of emulsifiers, and optionally in the presence of further active ingredients, such as ?-sympathomimetic drugs, e.g. oxymetazoline or xylometazoline, and related subjects of the invention.

Abstract: A first pharmacologically active substance contained in a pharmaceutical, which acts on a specific biological function, is released according to a predetermined release profile (D.1), FIG. 1, and generates a first activity profile (I.1) that has flank phases with increasing and decreasing activity intensity. For changing such flank phases, an additional pharmacologically active substance is used which acts on the same biological function and which is released according to a release profile (D.2) such that its activity profile (I.2) overlays the first activity profile (I.1) within the flank phase to be changed. For shortening an end flank phase, an additional substance is used whose activity is counter to the activity of the first substance and cancels, reduces, or overpowers this activity in its declining phase. Accordingly, with the aforementioned pharmaceutical, undesirable aftereffects of a pharmacologically active substance, for example, can be prevented.

Abstract: A first pharmacologically active substance contained in a pharmaceutical, which acts on a specific biological function, is released according to a predetermined release profile (D.1), FIG. 1, and generates a first activity profile (1.1) that has flank phases with increasing and decreasing activity intensity. For changing such flank phases, an additional pharmacologically active substance is used which acts on the same biological function and which is released according to a release profile (D.2) such that its activity profile (I.2) overlays the first activity profile (I.1) within the flank phase to be changed. For shortening an end flank phase, an additional substance is used whose activity is counter to the activity of the first substance and cancels, reduces, or overpowers this activity in its declining phase. Accordingly, with the aforementioned pharmaceutical, undesirable aftereffects of a pharmacologically active substance, for example, can be prevented.